Status:
COMPLETED
Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
Lead Sponsor:
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
HIV Infections
Eligibility:
All Genders
2-36 years
Phase:
PHASE2
Brief Summary
A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been shown to be an effective way of reducing the risk of mother-to-child trans...
Detailed Description
Single dose nevirapine (SD NVP) has greatly reduced the rate of mother-to-child transmission (MTCT) of HIV. Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are recommended for us...
Eligibility Criteria
Inclusion
- Inclusion Criteria for All Participants:\>\>
- age \>=6 months to \< 36 months (decreased to 2 months in protocol version 4.0)\>\>
- HIV infected\>\>
- Viral load greater than 5,000 copies/ml within 60 days of study entry\>\>
- Treatment naive except for antiretrovirals (ARV) used to prevent MTCT (infant ARV use for \<=1 week postpartum for prevention of MTCT allowed) \>\>
- Eligible for treatment according to WHO pediatric algorithm (updated in protocol version 1.0, Letter of amendment (LOA)#1) and protocol version 2.0, LOA#3). Subjects with active opportunistic infections were not eligible for study participation until they had been treated and were clinically stable \>\>
- Parent or legal guardian willing to provide signed informed consent\>\>
- Inclusion Criteria for Cohort I:\>\>
- Documentation of maternal or infant NVP exposure or a highly reliable verbal report. (Updated in protocol version 2.0, LOA#3 to require written clinic/hospital documentation of infant exposure to SD NVP)\>\>
- Use of maternal ARV, including NVP, permitted during pregnancy\>\>
- One or more of the following: strict formula feeding, initial infant HIV diagnosis occurring while younger than 60 days of age, or an initial AIDS-defining illness diagnosis by WHO criteria while younger than 60 days of age. \>\>
- Inclusion Criteria for Cohort II:\>\>
- Use of maternal ARVs, excluding NNRTIs, permitted during pregnancy\>\>
- Evidence of lack of prior NVP exposure (added in protocol version 2.0, LOA#3) by review of maternal and child medical records or health card (or other written documentation) for evidence of NVP exposure to mother or infant during pregnancy, labor, and delivery. If no written documentation showing lack of NVP use was shown in these records or if these records were not available for review, then a verbal report considered to be highly reliable by the study nurse was acceptable AND one or more of the following: \>\>
- Study subject born before single dose NVP was available for prevention of MTCT of HIV in the location of birth of study subject\>\>
- Study subject born before the biological mother's first positive HIV test\>\>
- Site staff had another reason to believe the subject had not been exposed to NVP \>\> \>\> Exclusion Criteria for All Participants:\>\>
- Grade 2 or higher aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at study screening\>\>
- Grade 3 or higher laboratory toxicity at study screening\>\>
- Received ARVs for anything other than the prevention of intrapartum MTCT. Infants who received ARVs after the first week of life (e.g., for the prevention of MTCT of HIV through breastfeeding) were excluded \>\>
- Acute serious infections requiring active treatment. Subjects could be receiving treatment for active TB if it did not include rifamycin drugs\>\>
- Receiving chemotherapy for an active tumor\>\>
- History of a cardiac conduction abnormality and underlying structural heart disease\>\>
- Required certain medications\>\> \>\> Exclusion Criteria for Cohort I: \>\>
- History of or currently breastfeeding. Breastfed infants with a positive HIV test or who had experienced an AIDS-defining illness by WHO criteria at 60 days of age or younger were not excluded\>\>
- Exclusion Criteria for Cohort II:\>\>
- Exposure to any maternal NVP or other NNRTI prior to or during the pregnancy or while breastfeeding\>\>
- Exposure of infant to NVP at any time including during the first week of life
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
452 Patients enrolled
Trial Details
Trial ID
NCT00307151
Start Date
December 1 2005
End Date
December 1 2016
Last Update
April 13 2017
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
BJ Medical College CRS
Pune, Maharashtra, India, 411001
2
University of North Carolina Lilongwe CRS
Mzimba Road, Lilongwe, Malawi
3
Nelson R. Mandela School of Medicine, University of Kwazulu
Natal, Durban, South Africa, 50202
4
University of Stellenbosch-Tygerberg Hospital, South Africa
Cape Town, South Africa, 7700